Mark J. Ratain to Cost-Benefit Analysis
This is a "connection" page, showing publications Mark J. Ratain has written about Cost-Benefit Analysis.
Connection Strength
1.487
-
Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders. Nat Rev Clin Oncol. 2024 May; 21(5):331-332.
Score: 0.776
-
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Ann Oncol. 2023 08; 34(8):638-644.
Score: 0.182
-
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021 03 20; 39(9):950-955.
Score: 0.155
-
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020 09; 108(3):487-493.
Score: 0.147
-
Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3.
Score: 0.078
-
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009 Sep-Oct; 15(5):426-30.
Score: 0.070
-
The tyranny of non-inferiority trials. Lancet Oncol. 2024 Oct; 25(10):e520-e525.
Score: 0.050
-
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
Score: 0.029